Related Experiment Video

Updated: Apr 21, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

13.3K

Recent advances in non-steroidal FXR antagonists development for therapeutic applications

Huang Huang, Yong Xu, Jin Zhu

  • 1Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Mei Long Road, Shanghai 200237, China. jianli@ecust.edu.cn.

Current Topics in Medicinal Chemistry
|November 13, 2014
PubMed

Insights

Selective Farnesoid X receptor (FXR) antagonists are crucial for treating metabolic diseases. Research focuses on developing non-steroidal FXR antagonists with diverse chemical structures for therapeutic applications.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Molecular Biology

Background:

  • Farnesoid X receptor (FXR) is a nuclear receptor vital for bile acid and cholesterol homeostasis.
  • FXR regulates genes involved in cholesterol, lipid, and glucose metabolism, primarily in the liver and intestine.
  • Low selectivity of current FXR agonists necessitates the development of highly selective antagonists.

Purpose of the Study:

  • To explore the development of selective non-steroidal Farnesoid X receptor (FXR) antagonists.
  • To identify novel chemical scaffolds for FXR antagonist drug discovery.
  • To provide therapeutic prospects for metabolic and inflammatory diseases.

Main Methods:

  • Review of existing literature on FXR antagonists.
  • Analysis of diverse chemical scaffolds, including AGN34, tuberatolides, atractylenolides, andrographolides, GW4064 derivatives, and 1,3,4-trisubstitutedpyrazolones.
  • Evaluation of FXR antagonist selectivity and therapeutic potential.

Main Results:

  • Several non-steroidal FXR antagonist scaffolds have been developed, demonstrating diverse chemical structures.
  • These antagonists offer potential for high selectivity towards FXR.
  • Promising therapeutic applications in inflammation, metabolic syndrome, diabetes, gallstones, and cancer.

Conclusions:

  • Non-steroidal FXR antagonists represent a promising therapeutic avenue.
  • Development of selective FXR antagonists is critical for targeted treatment of metabolic disorders.
  • Further research into these scaffolds could lead to novel drug candidates.

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

3.0K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.4K

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
6.6K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.9K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
2.2K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
5.7K
Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
9.0K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
108